Top 10 US Headlines: Market Bubbles, Fed Fallout & Midterm Maneuvering—July 23, 2026

U.S. IPO issuance just hit a record high. And according to one portfolio manager, that makes it one of the four horsemen of a market bubble. In episode 86, we covered the market shock after the Fed Chair's resignation. Today, that instability is getting a name and a number. Here are the other essential headlines for Thursday, July twenty-third. With the U.S. midterms just four months away, Washington has started to spiral. The jostling for control of the House and Senate is creating volatility, as markets try to price in what policies the Trump administration can actually push through. Speaking of the administration, Capital One executive Brian Johnson is set to appear before the Senate Banking Committee today.

He's Trump's nominee to lead the Consumer Financial Protection Bureau — the very agency the administration has previously tried to shut down. His hearing will be a major signal for the future of consumer finance regulation. President Trump also just announced a new plan for massive tariffs on imported generic medicines. The goal is to force production back to the United States. This follows a separate announcement of new, fifty percent tariffs on a wide range of Canadian goods, set to take effect on August nineteenth. The currency markets are already reacting. Speculators have raised their bearish bets against the Canadian dollar to the highest level EVER recorded among major currencies. Net short positions now stand at twelve-point-five billion dollars.

The loonie just hit a fourteen-month low. And the ripple effects of trade policy are showing up on store shelves. In China, egg prices have soared nearly forty-five percent. State media is calling them "rocket eggs," and the cause is being traced directly back to friction from U.S. trade policies. On a brighter note for some, the French market research firm Ipsos posted a three percent revenue rebound in its second quarter. That reverses a first-quarter decline and offers a small but significant sign of life in corporate spending. And for savers, there's finally some yield. The best CD rates are now hitting four-point-two-zero percent APY, a level unseen for years. Okay. Let's go back to the tariffs. Because this isn't just one policy.

It's a fundamental shift in strategy, and the generic drug plan is the blueprint. For the next two years — through July 2028 — imported generic drugs will remain duty-free. The administration says this is a grace period. A chance for companies to move. But here's the turn. In August 2028, a one-hundred-percent tariff kicks in. One year later, it jumps to TWO-HUNDRED percent. The stated goal, in the President's own words, is to "RESHORE Generic Pharmaceutical Production into America." It's a penalty for any company that doesn't build plants and equipment inside the U.S. within that two-year window. Now, think about what that means for the supply chain. It’s one of the most globalized systems in the world. Many finished drugs come from Europe, but the raw ingredients and the generics themselves rely heavily on India and China.

You can't just build a factory in Ohio and replicate that ecosystem overnight. It takes years. Decades, sometimes. This policy puts a gun to the head of the three massive distributors that control almost all U.S. pharmaceutical logistics. They now have two years to completely re-engineer how they source the most basic, essential medicines. This isn't just a tax. It's a forced relocation of an entire global industry. And it connects directly to the new tariffs on Canada and the ongoing friction with China. The strategy is clear: use tariffs not just for leverage, but to physically break and rebuild supply lines. To force manufacturing back onto U.S. soil, no matter the short-term cost or disruption. The era of assuming frictionless global trade is over.

Every supply chain is now a political statement, and every price tag is starting to tell that story.